Pharmacological disease models
Small molecules and excitotoxic agents can be used to pharmacologically induce disease models such as epilepsy, Parkinson's Disease, catalepsy, Schizophrenia, pain and diabetes models. Researchers can save up to 50% on excitotoxic agents - they are up to half the price of other suppliers.
(S)-(-)-Sulpiride (HB1836)
Description:Selective D2-like receptor antagonist. Active enantiomer.
Purity:>99%
(RS)-(±)-Sulpiride (HB1835)
Description:Standard D2-like dopamine receptor antagonist
Purity:>98%
Swinholide A (HB4100)
Description:Actin filament inhibitor. Disrupts actin cytoskeleton.
Purity:>97%
TAK 715 (HB0599)
Description:Potent, p-38 MAP kinase inhibitor. Wnt/β-catenin signaling inhibitor.
Purity:>99%
Talampanel (HB0600)
Description:Selective, non-competitive AMPA / kainate receptor antagonist
Purity:>98%
Tamoxifen (HB0601)
Description:Estrogen receptor antagonist/ partial agonist. May be used in genome engineering (e.g. CreER/ CRISPR-Cas9).
Purity:>99%
Tamoxifen Citrate (HB0602)
Description:Estrogen receptor antagonist/ partial agonist. May be used in genome engineering (e.g. CreER/ CRISPR-Cas9). Citrate salt.
Purity:>98%